New drug approved for colonoscopy preparation

(HealthDay) -- Prepopik (sodium picosulfate, magnesium oxide and citric acid) has been approved by the U.S. Food and Drug Administration for adults preparing for a colonoscopy, a diagnostic procedure to inspect the colon's inner lining.

The cleansing regimen consists of two packets of powder, each dissolved in water, to be taken at different times before a , the FDA said in a news release. Additional fluid intake is needed to prevent dehydration and electrolyte imbalance, the agency warned.

In two clinical studies involving about 1,200 adults preparing for a colonoscopy, the most common side effects of Prepopik included nausea, headache and vomiting.

As a condition of approval, maker Ferring Pharmaceuticals must conduct additional studies to evaluate the product's safety and effectiveness among children, the FDA said.

Ferring is based in Parsippany, N.J.

More information: To learn more about colonoscopy, visit the National Digestive Diseases Information Clearinghouse.

add to favorites email to friend print save as pdf

Related Stories

Two pancreatic-enzyme products approved

Mar 02, 2012

(HealthDay) -- Two drugs that supplement the digestion-aiding actions of pancreatic enzymes have been approved by the U.S. Food and Drug Administration, the agency said Thursday in a news release.

Study: Less prep needed for colonoscopy

May 02, 2010

Researchers at Henry Ford Hospital may have found a better way to prep patients for colonoscopy procedures so they no longer need to drink a gallon of prescribed fluids prior to the procedure.

Perjeta approved for advanced breast cancer

Jun 11, 2012

(HealthDay) -- Perjeta (pertuzumab) has been approved by the U.S. Food and Drug Administration to treat people with HER2-positive late-stage breast cancer, the agency said in a news release.

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

Oct 24, 2014

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments